Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

Source: Thailand Medical News  Apr 19, 2019  4 years, 11 months, 4 weeks, 1 day, 8 hours, 43 minutes ago

Healthcare Stocks To Watch Out For In April and May 2019

Healthcare Stocks To Watch Out For In April and May 2019
Source: Thailand Medical News  Apr 19, 2019  4 years, 11 months, 4 weeks, 1 day, 8 hours, 43 minutes ago
As usual, our advice from the team at Thailand Medical News is to focus on the US stock markets rather than the local stocks due to a variety of reasons. The US stock market looks as promising as ever especially when it comes to healthcare and biotech stocks. The U.S. soon will spend nearly 20% of its gross domestic product on health care. This comes as health care costs outpace the rise in inflation.

So smart investors are looking to cash in by eyeing key health care stocks. Headlines abound for biotech and pharma stocks with cutting-edge medicines. But health care stocks actually comprise a broader swath of medical companies — many of which are behind the scenes.

All these health care stocks share several commonalities: A streak of bullish earnings growth, as well as high Composite and Relative Strength ratings. The CR measures key growth metrics while the RS Rating looks at a stock's 12-month performance against all other stocks.

These Are The Top 5 Health Care Stocks Today:
  • Incyte (INCY)
  • ANI Pharmaceuticals (ANIP)
  • PRA Health Sciences (PRAH)
  • Veeva Systems (VEEV)
  • BioSpecifics Technologies (BSTC)
Incyte Stands Out Among Health Care Stocks
Incyte stock is ranked first among more than 500 biotech stocks. It has a key cancer treatment with Food and Drug Administration approval. Jakafi, under a partnership with Novartis (NVS), treats conditions that affect the bone marrow.
Health care stock leader Incyte also markets leukemia drug Iclusig in Europe, and is partnered with Eli Lilly (LLY) on rheumatoid arthritis medicine Olumiant. In 2018, Incyte collected $40 million in royalties from Olumiant sales. Iclusig sales were about $80 million.

In February, the FDA delayed a review of Jakafito treat graft vs. host disease, a complication of a stem cell transplant. In this, the patient's body begins rejecting the foreign donor material. But analysts downplayed the FDA decision, noting the government shutdown could have been at play.

Incyte stock also has best-possible Composite and EPS ratings of 99. Shares have an RS Rating of 91. The biotech stock is also listed as No. 24 on's list of 500 fast-growing stocks, with a five-year earnings growth rate of 105%.

ANI Pharma Joins The List Of Top Health Care Stocks
Drugmaker ANI Pharmaceuticals sells its prescription drugs to wholesalers and distributors, as well as pharmacy and retail outlets. ANI Pharma is a relatively small company with 2018 sales of $201.6 million. Revenue advanced 14% year over year in 2018.

ANI makes 33 generic drugs, as of late March. Notable among them is a knockoff of Johnson & Johnson's (JNJ) attention deficit hyperactivity disorder medicine Concerta. The current annual U.S. market for two strengths of the drug is about $505 million, ANI says.

The company also makes a generic version of Boehringer Ingelheim Pharmaceuticals' Aggrenox, a medicine aimed to reduce the risk of stroke in s